Navigation Links
Synta Pharmaceuticals to Host Conference Call Today

LEXINGTON, Mass.--(BUSINESS WIRE)--Jun 5, 2007 - Synta Pharmaceuticals Corp., (NASDAQ: SNTA) a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today announced it will hold a conference call at 2:30 p.m. (EST) today to discuss these results, which will be presented at the annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago, Illinois this morning.

The conference call will be webcast live over the Internet. The webcast can be accessed by logging on to the "Investors" section of Synta Pharmaceuticals' website, www.syntapharma.com, prior to the event.

The call also can be accessed by dialing (877) 407-8035 or (201) 689-8035 prior to the start of the call. The webcast will be archived on the Company's website.

About Synta Pharmaceuticals

Synta Pharmaceuticals Corp. is a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to extend and enhance the lives of patients with severe medical conditions, including cancer and chronic inflammatory diseases. Synta has a unique chemical compound library, an integrated discovery engine, and a diverse pipeline of clinical- and preclinical-stage drug candidates with distinct mechanisms of action and novel chemical structures. All Synta drug candidates were discovered and developed internally. For more information, please see www.syntapharma.com

Contact

Synta Pharmaceuticals Corp.
Rob Kloppenburg, 781-541-7125
or
MacDougall Biomedical Communications
Doug MacDougall, 508-647-0209


'"/>




Page: 1

Related medicine technology :

1. Synta Presents Results for STA-4783 in Metastatic Melanoma Showing Improvement in Overall Survival
2. Synta Oncology Candidate STA-4783 Clinical Trial Results to Be Presented at the ASCO Annual Meeting
3. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
4. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
6. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
7. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
8. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
9. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
10. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
11. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Synta Pharmaceuticals Host Conference Call Today
(Date:12/16/2009)... Scientists at,deCODE genetics, Inc. (Nasdaq: DCGN ... a version of a common single-letter variant in ... major impact on susceptibility to type 2,diabetes (T2D). ... only large, but unusual:,if an individual inherits it ... by more than 30% compared to those who ...
(Date:12/16/2009)... Wis., Dec. 16 EuroPharma, Inc. ... for the use of super absorbency BCM-95® ... EuroPharma formulations. The exclusive distribution territory ... health food store channel and professional channel, ... and clinics. BCM-95® is a highly ...
(Date:12/16/2009)... Inc. today announced the treatment of the first ... adhesive product, TissuGlu®. Initiation of the study marks ... the lead product toward clinical practice. ,, ... study to investigate the safety of TissuGlu and ... in abdominoplasty, or "tummy tuck," surgeries. The study ...
Breaking Medicine Technology:deCODE Discovers a Major Risk Factor for Type 2 Diabetes Dependent on Parent of Origin 2deCODE Discovers a Major Risk Factor for Type 2 Diabetes Dependent on Parent of Origin 3deCODE Discovers a Major Risk Factor for Type 2 Diabetes Dependent on Parent of Origin 4EuroPharma Exclusive Distributor of BCM-95 and BosPure 2EuroPharma Exclusive Distributor of BCM-95 and BosPure 3First Patient Treated in Clinical Study of Cohera Medical's TissuGlu(R) Surgical Adhesive 2First Patient Treated in Clinical Study of Cohera Medical's TissuGlu(R) Surgical Adhesive 3Rare genetic disease successfully reversed using stem cell transplantation 9972 1Rare genetic disease successfully reversed using stem cell transplantation 9972 2Rare genetic disease successfully reversed using stem cell transplantation 9972 3Micromet to Host Conference Call and Webcast to Discuss MT110 Data Presented at ECCO ESMO on September 22 2009 14130 1Micromet to Host Conference Call and Webcast to Discuss MT110 Data Presented at ECCO ESMO on September 22 2009 14130 2Micromet to Host Conference Call and Webcast to Discuss MT110 Data Presented at ECCO ESMO on September 22 2009 14130 3Trust for Americas Health Applauds HHS Announcement of Prevention and Wellness Fund of the American Recovery and Reinvestment Act 57556 1Trust for Americas Health Applauds HHS Announcement of Prevention and Wellness Fund of the American Recovery and Reinvestment Act 57556 2
... HARBIN, China, May 4 /PRNewswire-Asia-FirstCall/ -- China ... Medical" or "the Company") (Nasdaq: CSKI ), ... in the People,s Republic of China ("PRC"), today announced ... Sudden Cardiac Death (SCD) Early Examination Kit has been ...
... Australia, May 4 /PRNewswire-Asia-FirstCall/ -- Pharmaceutical,company Pharmaxis (ASX: PXS; ... positive,results of its recently completed international Phase III trial ... represents one of,the largest clinical trials conducted in cystic ... of the trial was to assess whether Bronchitol,improves lung ...
Other Medicine Technology:China Sky One Medical, Inc. Achieves Significant Breakthrough in Research for Sudden Cardiac Death (SCD) Early Examination Kit 2China Sky One Medical, Inc. Achieves Significant Breakthrough in Research for Sudden Cardiac Death (SCD) Early Examination Kit 3Pharmaxis Announces Positive Results of Phase 3 Cystic Fibrosis Trial 2Pharmaxis Announces Positive Results of Phase 3 Cystic Fibrosis Trial 3Pharmaxis Announces Positive Results of Phase 3 Cystic Fibrosis Trial 4Pharmaxis Announces Positive Results of Phase 3 Cystic Fibrosis Trial 5
(Date:12/16/2009)... that increase susceptibility to disease , , WEDNESDAY, Dec. ... increased susceptibility to leprosy have been identified by ... who analyzed more than 10,000 DNA samples from ... their discovery highlights the important role that the ... leprosy. , "Though leprosy is not common, the ...
(Date:12/16/2009)... GAINESVILLE, Fla. University of Florida researchers at work ... the first to predict the spread of the disease ... than 21 million calls to determine how often residents ... region composed of two islands off the coast of ... in recent years. Its government commissioned the study as ...
(Date:12/16/2009)... In animals, they cut bleeding time in half, but use ... (HealthDay News) -- Hoping to improve on nature, researchers have ... platelets, to be used in trauma or other cases where ... a core, with material that is used in degradable stitches, ... professor of biomedical engineering at Case Western Reserve University, and ...
(Date:12/16/2009)... campaign , ... Englewood, CO (Vocus) ... Hotbed Campaign as its largest yearly promotion for the ... MassBio and showcases 37 Massachusetts companies across biotechnology, pharmaceutical ... on an electronic and printed map that is ...
(Date:12/16/2009)... -- Shoppers like knowing if their salad is ... grocers have found it burdensome to implement the ... them to provide the information at point of ... for easily making grocery and produce signs ... require retailers of unprocessed fruits, vegetables and other ...
Breaking Medicine News(10 mins):Health News:Leprosy Genes Identified 2Health News:Scientists use cell phone records to predict spread of malaria 2Health News:Scientists use cell phone records to predict spread of malaria 3Health News:Synthetic Platelets Put the Brakes on Blood Loss 2Health News:Synthetic Platelets Put the Brakes on Blood Loss 3Health News:Thriving Bioscience Region Leaves Its Mark 2Health News:New Website Helps Grocers Comply With COOL Laws 2
... develops after exposure to combat or another extremely disturbing ... Vietnam combat veterans with post-traumatic stress disorder (PTSD) //when ... neurologic deficits. It suggests that these deficits are not ... predispose individuals to PTSD. The study was published in ...
... reports great improvement following her face transplant surgery done 5 ... newspaper that her facial scars are more healed and she's ... two has said she was under the influence of drugs ... ,Dinoire says her speech has improved, though it's still ...
... from the University of California, San Francisco it is found ... Hence he developed the simple forearm support which avoids the ... ,He studied 182 workers at a call centre ... They suffered less pain in the neck, shoulders, arm, wrist ...
... students of the country are expected to organize a nationwide ... ,The stir is against a government proposal to hike ... of that the matter will be considered by after the ... students. ,The strike on May 2 will be ...
... SA new drug is called the Acomplia which the European ... weight loss//. After this its shares rose 2.7%. The ... weight control. The chemical name of the drug is rimonabant ... But Sanofi failed to win the approval of the agency, ...
... people have so far succumbed to the malaria epidemic, which ... Till date 335,000 people have been infected with the disease. ... cerebral malaria since the disease struck in the state in ... Assam, which has a population of 26 million, is the ...
Other Medicine News:Health News:Brain Abnormalities Raise the Risk of PTSD 2Health News:Nationwide Strike on May 2nd by Medicos on Reservation Issue 2
NIDEK's US-1800 is an industry leader offering both combination pachymeter and ultrasound functionalities. The unit features and includes the latest IOL power calculation software, a touch screen pan...
... developed a minimally invasive cryocatheter to ... delivers a very high level of ... site precision, minimal tissue disruption, and ... ,Freezor is a flexible, single-use, minimally ...
Steerable catheter that is ideal for mapping unusual anatomy...
... specifically designed for use with our CARTO ... NAVI-STAR catheter houses a Biosense Webster sensor ... real time, exact location points from within ... information. The NAVI-STAR electro-anatomical navigation catheter is ...
Medicine Products: